Talk:GSK-3 inhibitor

A member of the Guild of Copy Editors, Miniapolis, reviewed a version of this article for copy editing on 13 January 2020. However, a major copy edit was inappropriate at that time because of the issues specified below, or the other tags now found on this article. Once these issues have been addressed, and any related tags have been cleared, please tag the article once again for {{copyedit}}. The Guild welcomes all editors with a good grasp of English. Visit our project page if you are interested in joining!
Please address the following issues as well as any other cleanup tags before re-tagging this article with copyedit: Open merge proposal

No merge

The following discussion is closed. Please do not modify it. Subsequent comments should be made in a new section. A summary of the conclusions reached follows.

To merge. Klbrain (talk) 13:09, 29 February 2020 (UTC)[reply]

I suggest that this be kept as a separate topic, as there is sufficient content to be stand alone. Graeme Bartlett (talk) 08:15, 9 December 2018 (UTC)[reply]

Merge @Graeme Bartlett: Unfortunately, I currently have little confidence in the ability of the creator of this article to utilise WP:RS to generate usefully constructed content, and have raised this on their talk page, following an AFD discussion on another of their creations. Unfortunately, the subject here is beyond my comprehension, but my instinct is to suggest that just a section on inhibitors, based on properly researched references merged from here into the article on GSK-3 would be better than a stand-alone article, unless, that is, you or another editor are able to apply sufficient expertise to ensure this isn't promotional nonsense or just a semi-scientific essay with a few random references thrown in. (As I draft this response, I note that the article creator has just been indefinitely blocked by Swarm per WP:NOTHERE.) Nick Moyes (talk) 00:50, 28 December 2018 (UTC)[reply]

Merge @Graeme Bartlett: Due to the diversity of potential mechanisms of action, and applications, it seems to me that a section on inhibitors should be (and is) included on GSK-3, and that the particular mechanisms of action for each Inhibitor should be mentioned on the relevant specific page, with an overview in the GSK-3 Inhibitors section of GSK-3. That is, I feel that the information on GSK-3 inhibitors wouldn't be cohesive enough to form a complete article since all you can do is describe some mechanisms, give examples, and explain the applications. If the article looked more like the article on MAOI, then I might consider No Merge, but unless that happens, I'd prefer to support a merge. Direwolf202 (talk) 18:04, 15 August 2019 (UTC)[reply]

Merge @Graeme Bartlett: Upon reviewing this article and GSK-3, a merge would simplify everything. The benefits section on this article is redundant, and we could supplement the individual medications on the GSK article itself. Moksha88 (talk) 03:00, 17 August 2019 (UTC)[reply]

Merge @Graeme Bartlett: I agree with all the points made by the other users. This article has a lot of issues that can be solved by incorporating into GSK-3. Firezzasd (talk) 18:41, 14 November 2019 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

References

While editing several sections, most recently 'Olanzapine,' the citations don't support the preceding text. Moksha88 (talk) 18:48, 20 August 2019 (UTC)[reply]